VX-814 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 231 | Alpha-1-antitrypsin deficiency | 5 |
231. Alpha-1-antitrypsin deficiency
Clinical trials : 89 / Drugs : 89 - (DrugBank : 16) / Drug target genes : 35 - Drug target pathways : 47
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003650-92-SE (EUCTR) | 08/05/2020 | 09/12/2019 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotype | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VX-814 INN or Proposed INN: VX-814 | Vertex Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 43 | Phase 2 | United States;Ireland;Netherlands;Germany;United Kingdom;Sweden | ||
| 2 | EUCTR2019-003650-92-IE (EUCTR) | 09/04/2020 | 10/03/2020 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotype | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VX-814 INN or Proposed INN: VX-814 | Vertex Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 43 | Phase 2 | Sweden;United Kingdom;Germany;Netherlands;Ireland;United States | ||
| 3 | EUCTR2019-003650-92-GB (EUCTR) | 28/02/2020 | 09/12/2019 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotype | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VX-814 INN or Proposed INN: VX-814 | Vertex Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 43 | Phase 2 | United States;Ireland;Netherlands;Germany;United Kingdom;Sweden | ||
| 4 | EUCTR2019-003650-92-DE (EUCTR) | 11/02/2020 | 04/12/2019 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotype | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VX-814 INN or Proposed INN: VX-814 | Vertex Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 43 | Phase 2 | United States;Ireland;Netherlands;Germany;United Kingdom;Sweden | ||
| 5 | NCT04167345 (ClinicalTrials.gov) | January 13, 2020 | 15/11/2019 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Alpha 1-Antitrypsin Deficiency | Drug: VX-814;Drug: Placebo | Vertex Pharmaceuticals Incorporated | NULL | Terminated | 18 Years | 80 Years | All | 48 | Phase 2 | United States;Canada;Germany;Ireland |